The present invention relates to nanostructured conjugates, more specifically to nanostructured fusion proteins suitable for the selective delivery of their conjugated therapeutic agents to specific cell and tissue types. It also relates to nanoparticles comprising such nanostructured proteins and the therapeutic uses thereof.

Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (SPIONs) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900 C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.

Use of a P-containing polymer for measuring .sup.31P-MRI, wherein the P-containing polymer is selected from polyphosphates, polyphosphonates, poly(phosphine oxide)s, polyphosphazenes, polyphosphinates, polyphosphoramidates, polyphosphorodiamidates, polyphosphoamides, polythionophosphates, and polythionophosphonates. A polyphosphonate copolymer and an aqueous suspension comprising micelles of the polyphosphonate copolymer.

There are described magnetic nanoparticles the surface of which is functionalized with catechol and constructs comprising a plurality of said nanoparticles encapsulated in a biocompatible polymer matrix, wherein a molecule with therapeutic action is optionally dispersed, said polymer matrix optionally being in turn further functionalized; there are further described cells of the immune system incorporating said polymeric constructs giving rise to their engineering.

The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity.

A magnetic resonance imaging (MRI) T1 contrast agent composition including T1 contrast material coated on the surface of a nanoparticle support and an imaging method using the MRI T1 contrast agent. The MRI T1 contrast agent composition has excellent T1 spin magnetic relaxation effects by modifying the paramagnetic T1 contrast material on the nanoparticle support having a certain diameter such that the paramagnetic T1 contrast material has a certain thickness or less, and thereby remarkably increasing the surface-to-volume ratio of the T1 contrast material. The MRI T1 contrast agent provides more precise and clear T1 positive contrast images, and is thus useful for highly reliable image diagnosis.

Described herein are particles comprising a crystalline matrix and a dopant, wherein one of the atoms of the matrix is .sup.19F and .sup.31P, or .sup.13C, .sup.15N, .sup.29Si, .sup.16O, .sup.17O, .sup.23Na, .sup.39K, .sup.25Mg, .sup.40Ca, .sup.43Ca or deuterium; and the dopant is a compound involved in a biological process in a mammalian organism; and wherein the dopant is present in an amount of between 0.01% and 20% of the plurality of particles, and wherein when the matrix comprises an atom selected from the group of .sup.13C, .sup.15N, .sup.29Si, .sup.16Q, .sup.17O, .sup.23Na, .sup.39K, .sup.25Mg, .sup.40Ca, .sup.43Ca and deuterium, and the dopant is isotopically enriched.

The present invention provides preparations of MSCs with important therapeutic potential. The MSC cells are non-primary cells with an antigen profile comprising less than about 1.25% CD45+ cells (or less than about 0.75% CD45+), at least about 95% CD105+ cells, and at least about 95% CD166+ cells. Optionally, MSCs of the present preparations are isogenic and can be expanded ex vivo and cryopreserved and thawed, yet maintain a stable and uniform phenotype. Methods are taught here of expanding these MSCs to produce a clinical scale therapeutic preparations and medical uses thereof.

Targeted contrast agents are provided for MRI of amyloid deposition.

Nanostructures that, after in vivo administration, are excreted in the urine via the kidneys without being phagocytosed by macrophages and/or metabolized, and their use as pharmaceutical compositions are disclosed. A nanostructure for in vivo administration contains (i) a spherical core formed by crosslinking one to three dextran molecules with an average molecular weight of 10,000 Da or less using a crosslinker and (ii) a discontinuous shell with divalent or trivalent iron ions coordinationally bonded to crosslinker-derived hydrophilic groups on the surface of the spherical core; and has (iii) a mass ratio of dextran to iron ranging from 100:2 to 100:10, and a charge ranging from 20 mV to 0 mV.